{"id":"prednisolone","rwe":[],"_fda":{"id":"bff1726c-7781-49de-8a61-bc37a755c92b","set_id":"00a5aa88-e361-4ea7-8922-530c738b726e","openfda":{"upc":["0311980180058","0311980180157","0311980180102"],"unii":["8B2807733D"],"route":["OPHTHALMIC"],"rxcui":["1376336","1548724"],"spl_id":["bff1726c-7781-49de-8a61-bc37a755c92b"],"brand_name":["PRED FORTE"],"spl_set_id":["00a5aa88-e361-4ea7-8922-530c738b726e"],"package_ndc":["11980-180-01","11980-180-06","11980-180-05","11980-180-10","11980-180-15","11980-180-11"],"product_ndc":["11980-180"],"generic_name":["PREDNISOLONE ACETATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["PREDNISOLONE ACETATE"],"manufacturer_name":["Allergan, Inc."],"application_number":["NDA017011"],"is_original_packager":[true]},"version":"16","warnings":["WARNINGS Prolonged use of corticosteroids may result in posterior subcapsular cataract formation and may increase intraocular pressure in susceptible individuals, resulting in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Prolonged use may also suppress the host immune response and thus increase the hazard of secondary ocular infections. If this product is used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be checked frequently. Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation. Acute purulent infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication. The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended. PRED FORTE ® suspension contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people."],"pregnancy":["Pregnancy Prednisolone has been shown to be teratogenic in mice when given in doses 1-10 times the human dose. Dexamethasone, hydrocortisone, and prednisolone were ocularly applied to both eyes of pregnant mice five times per day on days 10 through 13 of gestation. A significant increase in the incidence of cleft palate was observed in the fetuses of the treated mice. There are no adequate well-controlled studies in pregnant women. Prednisolone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from prednisolone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use The safety and effectiveness in pediatric patients have been established. Use in pediatric patients is supported by evidence from adequate and well-controlled studies of prednisolone acetate ophthalmic suspension in adults with additional data in pediatric patients. Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients."],"overdosage":["OVERDOSAGE Overdosage will not ordinarily cause acute problems. If accidentally ingested, drink fluids to dilute."],"description":["DESCRIPTION PRED FORTE ® (prednisolone acetate ophthalmic suspension, USP) 1% is a sterile, topical anti-inflammatory agent for ophthalmic use. Its chemical name is 11ß,17, 21-Trihydroxypregna-1,4-diene-3, 20-dione 21-acetate and it has the following structure: Each mL of PRED FORTE ® contains: Active: prednisolone acetate (microfine suspension) 1% Inactives: benzalkonium chloride as preservative; boric acid; edetate disodium; hypromellose; polysorbate 80; purified water; sodium bisulfite; sodium chloride; and sodium citrate. The pH during its shelf life ranges from 5.0 - 6.0. The following structure for PRED FORTE® (prednisolone acetate ophthalmic suspension, USP) 1% is a sterile, topical anti-inflammatory agent for ophthalmic use. Its chemical name is 11ß,17, 21-Trihydroxypregna-1,4-diene-3, 20-dione 21-acetate."],"precautions":["PRECAUTIONS General The initial prescription and renewal of the medication order beyond 20 milliliters of PRED FORTE ® suspension should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated. As fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid applications, fungal invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate. Information for P atients Advise patients that if eye inflammation or pain persists longer than 48 hours or becomes aggravated, they should consult a physician. Advise patients that to prevent eye injury or contamination, care should be taken to avoid touching the bottle tip to eyelids or to any other surface. The use of this bottle by more than one person may spread infection. Keep bottle tightly closed when not in use. Keep out of the reach of children. Advise patients that PRED FORTE ® suspension contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to application of PRED FORTE ® and may be reinserted 15 minutes following its administration. Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been conducted in animals or in humans to evaluate the potential of these effects."],"how_supplied":["HOW SUPPLIED PRED FORTE ® (prednisolone acetate ophthalmic suspension, USP) 1% is supplied sterile in opaque white LDPE plastic bottles with droppers with pink high impact polystyrene (HIPS) caps as follows: 1 mL in 5 mL bottle - NDC 11980-180-01 5 mL in 10 mL bottle - NDC 11980-180-05 10 mL in 15 mL bottle - NDC 11980-180-10 15 mL in 15 mL bottle - NDC 11980-180-15 Storage : Store at up to 25°C (77°F). Protect from freezing. Store in an upright position. Revised : 02 / 2024 Distributed by: AbbVie, Inc. North Chicago, IL 60064 © 2024 AbbVie. All rights reserved. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. v2.0USPI180 Shape Description automatically generated"],"geriatric_use":["Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients."],"pediatric_use":["Pediatric Use The safety and effectiveness in pediatric patients have been established. Use in pediatric patients is supported by evidence from adequate and well-controlled studies of prednisolone acetate ophthalmic suspension in adults with additional data in pediatric patients."],"effective_time":"20240202","nursing_mothers":["Nursing Mothers It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from prednisolone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother."],"adverse_reactions":["ADVERSE REACTIONS The following adverse reactions have been identified during use of PRED FORTE ® . Because reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions include elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing. The development of secondary ocular infection (bacterial, fungal, and viral) has occurred. Fungal and viral infections of the cornea are particularly prone to develop coincidentally with long-term applications of steroids. The possibility of fungal invasion should be considered in any persistent corneal ulceration where steroid treatment has been used (see PRECAUTIONS ). Other adverse reactions reported with the use of prednisolone acetate ophthalmic suspension include: allergic reactions; dysgeusia; eye pain; foreign body sensation; headache; pruritus; rash; transient burning and stinging upon instillation and other minor symptoms of ocular irritation; urticaria; and visual disturbance (blurry vision). Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids. Corticosteroid-containing preparations have also been reported to cause acute anterior uveitis and perforation of the globe."],"contraindications":["CONTRAINDICATIONS PRED FORTE ® suspension is contraindicated in acute untreated purulent ocular infections, in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. PRED FORTE ® suspension is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids."],"general_precautions":["General The initial prescription and renewal of the medication order beyond 20 milliliters of PRED FORTE ® suspension should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated. As fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid applications, fungal invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Prednisolone acetate is a glucocorticoid that, on the basis of weight, has 3 to 5 times the anti-inflammatory potency of hydrocortisone. Glucocorticoids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as well as capillary proliferation, deposition of collagen, and scar formation."],"indications_and_usage":["INDICATIONS AND USAGE PRED FORTE ® is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe."],"information_for_patients":["Information for P atients Advise patients that if eye inflammation or pain persists longer than 48 hours or becomes aggravated, they should consult a physician. Advise patients that to prevent eye injury or contamination, care should be taken to avoid touching the bottle tip to eyelids or to any other surface. The use of this bottle by more than one person may spread infection. Keep bottle tightly closed when not in use. Keep out of the reach of children. Advise patients that PRED FORTE ® suspension contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to application of PRED FORTE ® and may be reinserted 15 minutes following its administration."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Shake well before using. Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated (see PRECAUTIONS )."],"spl_product_data_elements":["PRED FORTE prednisolone acetate PREDNISOLONE ACETATE PREDNISOLONE BENZALKONIUM CHLORIDE BORIC ACID EDETATE DISODIUM HYPROMELLOSE, UNSPECIFIED POLYSORBATE 80 WATER SODIUM BISULFITE SODIUM CHLORIDE SODIUM CITRATE, UNSPECIFIED FORM"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL NDC 11980-180-05 abbvie Rx Only PRED FORTE ® (prednisolone acetate ophthalmic suspension, USP) 1% sterile 5 mL PRINCIPAL DISPLAY PANEL NDC 11980-180-05 abbvie Rx Only PRED FORTE® (prednisolone acetate ophthalmic suspension, USP) 1% sterile 5 mL","PRINCIPAL DISPLAY PANEL NDC 11980-180-10 a bbvie Rx Only PRED FORTE ® (prednisolone acetate ophthalmic suspension, USP) 1% sterile 10 mL PRINCIPAL DISPLAY PANEL NDC 11980-180-10 abbvie Rx Only PRED FORTE® (prednisolone acetate ophthalmic suspension, USP) 1% sterile 10 mL","PRINCIPAL DISPLAY PANEL NDC 11980-180-15 abbvie Rx Only PRED FORTE ® (prednisolone acetate ophthalmic suspension, USP) 1% sterile 15 mL PRINCIPAL DISPLAY PANEL NDC 11980-180-15 abbvie Rx Only PRED FORTE® (prednisolone acetate ophthalmic suspension, USP) 1% sterile 15 mL"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been conducted in animals or in humans to evaluate the potential of these effects."]},"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"15159 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"13282 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"8528 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"7123 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"7055 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"6838 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"6003 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"5653 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"5332 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"5197 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Weight gain","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased appetite","drugRate":"","severity":"common","organSystem":""},{"effect":"Fluid retention","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypertension","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased sweating","drugRate":"","severity":"common","organSystem":""},{"effect":"Facial erythema","drugRate":"","severity":"common","organSystem":""},{"effect":"Edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Malaise","drugRate":"","severity":"common","organSystem":""},{"effect":"Hirsutism","drugRate":"","severity":"common","organSystem":""},{"effect":"Menstrual irregularities","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal distention","drugRate":"","severity":"common","organSystem":""},{"effect":"Suppression of growth in children","drugRate":"","severity":"common","organSystem":""},{"effect":"Sodium retention","drugRate":"","severity":"common","organSystem":""},{"effect":"Potassium loss","drugRate":"","severity":"common","organSystem":""},{"effect":"Decreased carbohydrate tolerance","drugRate":"","severity":"common","organSystem":""},{"effect":"Petechiae and ecchymoses","drugRate":"","severity":"common","organSystem":""},{"effect":"Impaired wound healing","drugRate":"","severity":"common","organSystem":""},{"effect":"Thin fragile skin","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Anastomosis of intestine","Anemia due to enzyme deficiency","Arginase deficiency","Arginosuccinate Lyase Deficiency","Atrophoderma","Avascular necrosis of bone","Bacterial infection of eye","Bilateral cataracts","Cerebral malaria","Cerebral trauma","Chronic heart failure","Cirrhosis of liver","Citrullinemia","Congenital hyperammonemia, type I","Deficiency of glucose-6-phosphate dehydrogenase","Diabetes mellitus","Disorder of muscle","Diverticulitis of gastrointestinal tract","Edema","Exposure to varicella","Eye infection","Fungal infection of eye","Gastritis","Herpes simplex","Herpes simplex dendritic keratitis","Herpes simplex keratitis","Hypercholesterolemia","Hyperglycemia","Hypertensive disorder","Hypokalemia","Hypopituitarism","Hypothyroidism","Immunosuppression","Inactive tuberculosis","Infection by Strongyloides","Infectious disease","Injury of eye region","Krukenberg spindle","Measles","Muscle atrophy","Mycosis","Ocular hypertension","Open-angle glaucoma","Ophthalmic herpes simplex","Ornithine Carbamyltransferase Deficiency","Osteopenia","Osteoporosis","Pathological fracture","Peptic ulcer","Porphyria","Pregnancy, function","Psychotic disorder","Seizure disorder","Severe myopia","Skin striae","Telangiectasia disorder","Traumatic rupture of tendon","Tuberculosis","Tuberculosis of eye","Vaccinia keratitis","Varicella-zoster virus infection","Viral eye infection"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Peptic ulcer with possible perforation and hemorrhage","drugRate":"","severity":"serious"},{"effect":"Congestive heart failure","drugRate":"","severity":"serious"},{"effect":"Aseptic necrosis of femoral and humeral heads","drugRate":"","severity":"serious"},{"effect":"Osteoporosis","drugRate":"","severity":"serious"},{"effect":"Pathologic fracture of long bones","drugRate":"","severity":"serious"},{"effect":"Vertebral compression fractures","drugRate":"","severity":"serious"},{"effect":"Pancreatitis","drugRate":"","severity":"serious"},{"effect":"Convulsions","drugRate":"","severity":"serious"},{"effect":"Posterior subcapsular cataracts","drugRate":"","severity":"serious"},{"effect":"Increased intracranial pressure with papilledema","drugRate":"","severity":"serious"}]},"status":"approved","trials":["NCT02780583","NCT00053105","NCT00804531","NCT04493853","NCT00443430","NCT00991744","NCT03933631","NCT03229538","NCT01214226","NCT03059979","NCT06038422","NCT02459392","NCT02532777","NCT06000709","NCT02253966","NCT02116075","NCT02981212","NCT04509219","NCT01281748","NCT05930236","NCT04599634","NCT06405100","NCT05058287","NCT06131593","NCT03647852","NCT04270409","NCT05927233","NCT03942887","NCT01205984","NCT03393949","NCT03383328","NCT04661007","NCT04323592","NCT03626376","NCT00076752","NCT07255248","NCT05232825","NCT02162810","NCT02651350","NCT03578276","NCT00433225","NCT01017510","NCT00367497","NCT04791345","NCT04501367","NCT00004357","NCT03721965","NCT00404469","NCT00426101","NCT00048165"],"aliases":["Prelone","Orapred","Pediapred"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.1281/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$46","description":"PREDNISOLONE 15 MG/5 ML SOLN","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=prednisolone","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:42:32.639831+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:42:39.100642+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:42:31.277684+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=prednisolone","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:42:39.982892+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:42:29.979224+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:42:29.979267+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:42:41.575816+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucocorticoid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:42:40.586237+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201014/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:42:40.480349+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA017011","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:42:29.979275+00:00"}},"allNames":"prelone","offLabel":[],"timeline":[],"aiSummary":"Prednisolone is the active form of prednisone, approved in 1955 and available generically. Preferred over prednisone in liver impairment and pediatric patients. Available in oral, ophthalmic, and injectable formulations.","brandName":"Prelone","companyId":"unknown","ecosystem":[],"mechanism":{"target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","novelty":"","modality":"Small molecule","drugClass":"Glucocorticoid (corticosteroid)","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:42:44.927314+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"companyName":"Generic (originally Schering)","competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"prednisolone","indications":{"approved":[{"name":"Acquired thrombocytopenia","diseaseId":"acquired-thrombocytopenia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Acute lymphoid leukemia","diseaseId":"acute-lymphoid-leukemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Adrenal cortical hypofunction","diseaseId":"adrenal-cortical-hypofunction","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Adrenogenital disorder","diseaseId":"adrenogenital-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Allergic bronchopulmonary aspergillosis","diseaseId":"allergic-bronchopulmonary-aspergillosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Allergic conjunctivitis","diseaseId":"allergic-conjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Allergic rhinitis","diseaseId":"allergic-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Angioedema","diseaseId":"angioedema","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Ankylosing spondylitis","diseaseId":"ankylosing-spondylitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Articular gout","diseaseId":"articular-gout","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Aspiration pneumonitis","diseaseId":"aspiration-pneumonitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Asthma","diseaseId":"asthma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Atopic dermatitis","diseaseId":"atopic-dermatitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Autoimmune disease","diseaseId":"autoimmune-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Autoimmune hemolytic anemia","diseaseId":"autoimmune-hemolytic-anemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial conjunctivitis","diseaseId":"bacterial-conjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial keratitis","diseaseId":"bacterial-keratitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Berylliosis","diseaseId":"berylliosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Blepharoconjunctivitis","diseaseId":"blepharoconjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bursitis","diseaseId":"bursitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Cerebral edema","diseaseId":"cerebral-edema","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Congenital adrenal hyperplasia","diseaseId":"congenital-adrenal-hyperplasia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Congenital hypoplastic anemia","diseaseId":"congenital-hypoplastic-anemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Contact dermatitis","diseaseId":"contact-dermatitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Corneal abrasion","diseaseId":"corneal-abrasion","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Corneal ulcer","diseaseId":"corneal-ulcer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Crohn's disease","diseaseId":"crohn's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Cyclitis","diseaseId":"cyclitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Dacryocystitis","diseaseId":"dacryocystitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Dermatitis herpetiformis","diseaseId":"dermatitis-herpetiformis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Diagnostic Test for Cushing's Syndrome","diseaseId":"diagnostic-test-for-cushing's-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Discoid lupus erythematosus","diseaseId":"discoid-lupus-erythematosus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Disorder of eye","diseaseId":"disorder-of-eye","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Disorder of musculoskeletal system","diseaseId":"disorder-of-musculoskeletal-system","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Disorder of skin","diseaseId":"disorder-of-skin","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Edema of larynx","diseaseId":"edema-of-larynx","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Eosinophilic asthma","diseaseId":"eosinophilic-asthma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Epicondylitis","diseaseId":"epicondylitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Eruption of skin","diseaseId":"eruption-of-skin","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Erythema multiforme","diseaseId":"erythema-multiforme","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Erythroblastic Anemia","diseaseId":"erythroblastic-anemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Erythroderma","diseaseId":"erythroderma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Exacerbation of asthma","diseaseId":"exacerbation-of-asthma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Extrinsic allergic alveolitis","diseaseId":"extrinsic-allergic-alveolitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Fibrosis of lung","diseaseId":"fibrosis-of-lung","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Follicular non-Hodgkin's lymphoma","diseaseId":"follicular-non-hodgkin's-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Giant cell arteritis","diseaseId":"giant-cell-arteritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Granuloma annulare","diseaseId":"granuloma-annulare","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Herpes zoster keratitis","diseaseId":"herpes-zoster-keratitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hodgkin's disease","diseaseId":"hodgkin's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Humoral hypercalcemia of malignancy","diseaseId":"humoral-hypercalcemia-of-malignancy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Idiopathic thrombocytopenic purpura","diseaseId":"idiopathic-thrombocytopenic-purpura","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infective blepharitis","diseaseId":"infective-blepharitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Inflammatory bowel disease","diseaseId":"inflammatory-bowel-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Iridocyclitis","diseaseId":"iridocyclitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Iritis","diseaseId":"iritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Juvenile rheumatoid arthritis","diseaseId":"juvenile-rheumatoid-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Keratitis","diseaseId":"keratitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Lichen simplex chronicus","diseaseId":"lichen-simplex-chronicus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Löffler's syndrome","diseaseId":"löffler's-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Meibomianitis","diseaseId":"meibomianitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Miliary tuberculosis","diseaseId":"miliary-tuberculosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Multiple sclerosis","diseaseId":"multiple-sclerosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Mycosis fungoides","diseaseId":"mycosis-fungoides","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Nephrotic syndrome","diseaseId":"nephrotic-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Non-Hodgkin's lymphoma","diseaseId":"non-hodgkin's-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Ocular rosacea","diseaseId":"ocular-rosacea","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pemphigus","diseaseId":"pemphigus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Plaque psoriasis","diseaseId":"plaque-psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumocystosis jiroveci pneumonia","diseaseId":"pneumocystosis-jiroveci-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Polymyalgia rheumatica","diseaseId":"polymyalgia-rheumatica","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Post traumatic osteoarthritis","diseaseId":"post-traumatic-osteoarthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Post-Op Ocular Inflammation","diseaseId":"post-op-ocular-inflammation","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Primary adrenocortical insufficiency","diseaseId":"primary-adrenocortical-insufficiency","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Primary cutaneous T-cell lymphoma","diseaseId":"primary-cutaneous-t-cell-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Progressive Diffuse Large B-Cell Lymphoma","diseaseId":"progressive-diffuse-large-b-cell-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pruritus ani","diseaseId":"pruritus-ani","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pruritus of genital organs","diseaseId":"pruritus-of-genital-organs","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Psoriasis","diseaseId":"psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Psoriasis with arthropathy","diseaseId":"psoriasis-with-arthropathy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Punctate keratopathy","diseaseId":"punctate-keratopathy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rheumatic heart disease","diseaseId":"rheumatic-heart-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rheumatoid arthritis","diseaseId":"rheumatoid-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rosacea","diseaseId":"rosacea","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sarcoidosis","diseaseId":"sarcoidosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Scalp psoriasis","diseaseId":"scalp-psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Seborrheic dermatitis","diseaseId":"seborrheic-dermatitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Severe Ocular Inflammation","diseaseId":"severe-ocular-inflammation","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Severe adrenal insufficiency","diseaseId":"severe-adrenal-insufficiency","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sjögren's syndrome","diseaseId":"sjögren's-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Stevens-Johnson syndrome","diseaseId":"stevens-johnson-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Superficial Ocular Infection","diseaseId":"superficial-ocular-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sympathetic uveitis","diseaseId":"sympathetic-uveitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Synovitis","diseaseId":"synovitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Synovitis due to Osteoarthritis","diseaseId":"synovitis-due-to-osteoarthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Systemic Dermatomyositis","diseaseId":"systemic-dermatomyositis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Systemic lupus erythematosus","diseaseId":"systemic-lupus-erythematosus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tendinitis","diseaseId":"tendinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tenosynovitis","diseaseId":"tenosynovitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Thyroiditis","diseaseId":"thyroiditis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Transfusion Reaction Urticaria","diseaseId":"transfusion-reaction-urticaria","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Transfusion reaction due to serum protein reaction","diseaseId":"transfusion-reaction-due-to-serum-protein-reaction","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Transplanted organ rejection","diseaseId":"transplanted-organ-rejection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Ulcerative colitis","diseaseId":"ulcerative-colitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Uveitis","diseaseId":"uveitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02780583","phase":"Phase 1","title":"Randomized Placebo Controlled Trial of Subcutaneous rhIL-1A (Anakinra) in the Management of Hospitalized Pediatric and Adult Patients With Macrophage Activation Syndrome","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","isPivotal":false,"enrollment":9,"indication":"Macrophage Activation Syndrome","completionDate":"2024-04-30"},{"nctId":"NCT00053105","phase":"Phase 1","title":"A Phase I Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin in the Treatment of Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Theradex","isPivotal":false,"enrollment":0,"indication":"Lymphoma","completionDate":""},{"nctId":"NCT00804531","phase":"Phase 4","title":"Intra-discal Steroid Injection for MODIC I Discopathy: A Randomized Control Trial","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","isPivotal":false,"enrollment":137,"indication":"Back Pain Lower Back Chronic","completionDate":"2015-11"},{"nctId":"NCT04493853","phase":"Phase 3","title":"A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","isPivotal":true,"enrollment":1012,"indication":"Hormone-Sensitive Prostate Cancer","completionDate":"2027-03-29"},{"nctId":"NCT00443430","phase":"Phase 4","title":"Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT in JIA)","status":"COMPLETED","sponsor":"Seattle Children's Hospital","isPivotal":false,"enrollment":85,"indication":"Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis","completionDate":"2010-10"},{"nctId":"NCT00991744","phase":"Phase 3","title":"Phase III Randomised Study on Liposomal Cytarabine (DepoCyte®) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 ","status":"SUSPENDED","sponsor":"Nordic Society for Pediatric Hematology and Oncology","isPivotal":true,"enrollment":100,"indication":"Acute Lymphoblastic Leukemia","completionDate":"2018-12"},{"nctId":"NCT03933631","phase":"Phase 3","title":"A Prospective Randomized Control Trial of Pilocarpine Use After Combined Cataract/Kahook Dual Blade Surgery","status":"RECRUITING","sponsor":"Montefiore Medical Center","isPivotal":true,"enrollment":142,"indication":"Glaucoma","completionDate":"2028-12"},{"nctId":"NCT03229538","phase":"Phase 3","title":"STeroids to REduce Systemic Inflammation After Infant Heart Surgery (STRESS)","status":"COMPLETED","sponsor":"Kevin Hill","isPivotal":true,"enrollment":1263,"indication":"Congenital Heart Disease in Children, Inflammatory Response","completionDate":"2022-03-31"},{"nctId":"NCT01214226","phase":"Phase 3","title":"Evaluation of the Survival Benefit of the Adjunction of Pentoxifylline to Corticosteroids in Patients Suffering From Severe Alcoholic Hepatitis","status":"COMPLETED","sponsor":"University Hospital, Lille","isPivotal":true,"enrollment":278,"indication":"Alcoholic Hepatitis, Alcoholic Liver Disease","completionDate":"2011-01"},{"nctId":"NCT03059979","phase":"EARLY/Phase 1","title":"Hit Hard and Early. The Effect of High Dose Methylprednisolone on Nailfold Capillary Changes and Biomarkers in Early SSc: a 12-week Randomised Explorative Double-blind Placebo-controlled Trial.","status":"UNKNOWN","sponsor":"Radboud University Medical Center","isPivotal":false,"enrollment":30,"indication":"Systemic Sclerosis, Raynaud Phenomena","completionDate":"2021-07-01"},{"nctId":"NCT06038422","phase":"Phase 3","title":"Clinical Study on Efficacy and Safety of GTP Regimen in the Treatment of Refractory/Recurrent Hemophagocytic Lymphohistiocytosis","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","isPivotal":true,"enrollment":15,"indication":"Refractory, Recurrence","completionDate":"2025-09-15"},{"nctId":"NCT02459392","phase":"NA","title":"EuroPainClinics® Study II (Prospective Randomized Double Blinded Trial)","status":"COMPLETED","sponsor":"EPC Education s.r.o.","isPivotal":false,"enrollment":300,"indication":"Lumbar Spinal Stenosis","completionDate":"2021-12-31"},{"nctId":"NCT02532777","phase":"Phase 2","title":"The Research of Standard Diagnosis and Treatment for Henoch-Schonlein Purpura Nephritis in Children","status":"UNKNOWN","sponsor":"Nanjing Children's Hospital","isPivotal":false,"enrollment":100,"indication":"Henoch-Schoenlein Purpura Nephritis","completionDate":"2020-07"},{"nctId":"NCT06000709","phase":"Phase 4","title":"Randomized, Double-blinded, Comparison Between Ultrasound-Guided Genicular Nerve Phenol Neurolysis and Intra-articular Steroid Injections","status":"UNKNOWN","sponsor":"University of Manitoba","isPivotal":false,"enrollment":40,"indication":"Osteoarthritis, Knee, Chronic Knee Pain","completionDate":"2024-07-31"},{"nctId":"NCT02253966","phase":"Phase 2","title":"","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","isPivotal":false,"enrollment":48,"indication":"Knee Joint Osteoarthrosis, Hyperalgesia","completionDate":"2016-03"},{"nctId":"NCT02116075","phase":"Phase 2","title":"","status":"UNKNOWN","sponsor":"Naveed Natanzi","isPivotal":false,"enrollment":50,"indication":"no Conditions","completionDate":""},{"nctId":"NCT02981212","phase":"Phase 4","title":"Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropa","status":"UNKNOWN","sponsor":"Yonsei University","isPivotal":false,"enrollment":100,"indication":"IgA Nephropathy","completionDate":"2018-10"},{"nctId":"NCT04509219","phase":"Phase 1","title":"Methylprednisolone Pulse Therapy for Coronary Artery Dilatation or Aneurysm Formation in Kawasaki Disease","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","isPivotal":false,"enrollment":10,"indication":"Mucocutaneous Lymph Node Syndrome","completionDate":"2023-08-31"},{"nctId":"NCT01281748","phase":"Phase 4","title":"","status":"TERMINATED","sponsor":"Hospital Universitario Getafe","isPivotal":false,"enrollment":83,"indication":"COPD","completionDate":"2009-07"},{"nctId":"NCT05930236","phase":"NA","title":"Ultrasound-guided Medial Lumbar Bundle Branch Block by Caudal-cranial Approach: Radiographic Comparison of a New Ultrasound-guided Method","status":"UNKNOWN","sponsor":"Erasme University Hospital","isPivotal":false,"enrollment":40,"indication":"Chronic Low-back Pain, Lumbar Facet Joint Syndrome","completionDate":"2024-06"},{"nctId":"NCT04599634","phase":"Phase 1","title":"A Phase 1 Study of Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":11,"indication":"Follicular Lymphoma, Marginal Zone Lymphoma","completionDate":"2024-06-20"},{"nctId":"NCT06405100","phase":"Phase 3","title":"Efficacy and Safety of Tacrolimus in Combination With Anti-CD20 Monoclonal Antibody (Ripertamab) in the Initial Treatment of Patients With Minimal Change Disease: a Multi-center Randomized Controlled ","status":"NOT_YET_RECRUITING","sponsor":"Air Force Military Medical University, China","isPivotal":true,"enrollment":81,"indication":"Minimal Change Disease","completionDate":"2027-04"},{"nctId":"NCT05058287","phase":"Phase 3","title":"Topical Epidural Steroid Usage in Patients Undergoing Posterior Lumbar Decompression: A Randomized Control Trial","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","isPivotal":true,"enrollment":150,"indication":"Opioid Use, Lumbar Spinal Stenosis","completionDate":"2026-12-31"},{"nctId":"NCT06131593","phase":"NA","title":"TAP Block With Dexamethasone Versus TAP Block With Methyl-prednisolone as a Pain Treatment Modality After Total Abdominal Hysterectomy Procedures: Randomized Controlled Trial","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","isPivotal":false,"enrollment":50,"indication":"Local Anesthetic, Ultrasound","completionDate":"2024-04-20"},{"nctId":"NCT03647852","phase":"NA","title":"Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","isPivotal":false,"enrollment":150,"indication":"Henoch-Schönlein Purpura","completionDate":"2026-10-30"},{"nctId":"NCT04270409","phase":"Phase 3","title":"A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smolde","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","isPivotal":true,"enrollment":337,"indication":"Plasma Cell Myeloma","completionDate":"2033-10-21"},{"nctId":"NCT05927233","phase":"Phase 4","title":"Effect of Methylprednisolone on Systemic Inflammatory Response and Clinical Parameters During Pediatric Congenital Open-Heart Surgery: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Aga Khan University","isPivotal":false,"enrollment":60,"indication":"Cyanotic Heart Disease, Cardiopulmonary Bypass","completionDate":"2025-06-30"},{"nctId":"NCT03942887","phase":"Phase 3","title":"Evaluating Clinical and Immunological Effects of Rituximab With Cyclophosphamide Compared to Rituximab Alone in AAV Patients","status":"UNKNOWN","sponsor":"Leiden University Medical Center","isPivotal":true,"enrollment":100,"indication":"ANCA Associated Vasculitis","completionDate":"2025-04-01"},{"nctId":"NCT01205984","phase":"Phase 4","title":"Efficacy and Tolerability of Systemic Methylprednisolone in Children and Adolescents With Chronic Rhinosinusitis","status":"COMPLETED","sponsor":"Ondokuz Mayıs University","isPivotal":false,"enrollment":48,"indication":"Chronic Rhinosinusitis, Children","completionDate":"2010-04"},{"nctId":"NCT03393949","phase":"Phase 4","title":"Effect of Preoperative Low-dose of Methylprednisolone on Postoperative Pain and Immune Functions After Video-assisted Thoracoscopic Surgery: A Prospective Randomized Controlled Trial","status":"COMPLETED","sponsor":"Shengjing Hospital","isPivotal":false,"enrollment":112,"indication":"Methylprednisolone, Immunological Function","completionDate":"2017-01-15"},{"nctId":"NCT03383328","phase":"Phase 4","title":"Effect of Drop-less Surgery Compared to Topical NSAID Alone and Combination of Steroid and NSAID on Central Macular Thickness After Cataract Surgery, a Randomized Controlled Trial","status":"COMPLETED","sponsor":"Line Kessel","isPivotal":false,"enrollment":470,"indication":"Postoperative Cystoid Macular Edema, Irvine-Gass Syndrome","completionDate":"2019-12-18"},{"nctId":"NCT04661007","phase":"Phase 1","title":"A Phase 1b/2 Study of Tafasitamab, Tafasitamab Plus Lenalidomide, Tafasitamab Plus Parsaclisib, and Tafasitamab Plus Lenalidomide in Combination With R-CHOP in Japanese Participants With Non-Hodgkin L","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Biosciences Japan GK","isPivotal":false,"enrollment":72,"indication":"Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma","completionDate":"2026-12-31"},{"nctId":"NCT04323592","phase":"N/A","title":"Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome","status":"COMPLETED","sponsor":"University of Trieste","isPivotal":false,"enrollment":173,"indication":"Severe Acute Respiratory Syndrome (SARS) Pneumonia, Coronavirus Infections","completionDate":"2020-05-10"},{"nctId":"NCT03626376","phase":"Phase 4","title":"A Randomized Trial of Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis","status":"WITHDRAWN","sponsor":"NYU Langone Health","isPivotal":false,"enrollment":0,"indication":"Herpes Simplex Virus Keratitis","completionDate":"2022-03-02"},{"nctId":"NCT00076752","phase":"Phase 2","title":"A Pilot Study of Intensified Lymphodepletion Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":9,"indication":"Lupus Erythematosus, Systemic","completionDate":"2013-10-15"},{"nctId":"NCT07255248","phase":"Phase 4","title":"Hoffa's Fat Pad Impingement (HFPI): Saline Injection Verus Ultrasound Guided Cortisone Injection: A Randomized Trial in Adolescent Female Athletes","status":"RECRUITING","sponsor":"Boston Children's Hospital","isPivotal":false,"enrollment":62,"indication":"Hoffa's Fat Pad Impingement","completionDate":"2028-01-02"},{"nctId":"NCT05232825","phase":"Phase 3","title":"A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Scleros","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":true,"enrollment":236,"indication":"Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis","completionDate":"2025-06-06"},{"nctId":"NCT02162810","phase":"NA","title":"Effect of Steroids on Post-Operative Complications Following Proximal Hypospadias Repair","status":"TERMINATED","sponsor":"Francis Schneck","isPivotal":false,"enrollment":28,"indication":"Hypospadias","completionDate":"2022-05"},{"nctId":"NCT02651350","phase":"Phase 1","title":"A Randomized Controlled Clinical Trial on the Efficacy and Safety of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-induced Liver Injury","status":"COMPLETED","sponsor":"Beijing 302 Hospital","isPivotal":false,"enrollment":80,"indication":"Drug-induced Liver Injury,Chronic","completionDate":"2019-07"},{"nctId":"NCT03578276","phase":"Phase 4","title":"Lessdrops™ Prophylactic Treatment After Routine Phacoemulsification Compared to Standard Drops Regimen","status":"COMPLETED","sponsor":"Carolina Eyecare Physicians, LLC","isPivotal":false,"enrollment":35,"indication":"Cataract","completionDate":"2019-12-04"},{"nctId":"NCT00433225","phase":"Phase 4","title":"","status":"COMPLETED","sponsor":"Innovative Medical","isPivotal":false,"enrollment":0,"indication":"Macula Thickening","completionDate":""},{"nctId":"NCT01017510","phase":"NA","title":"Comparative Study Examining the Effectiveness in Use of a DERMOJET and a Normal Syringe Treatment for Patients With Hair Loss - Alopecia Areata","status":"UNKNOWN","sponsor":"Sheba Medical Center","isPivotal":false,"enrollment":20,"indication":"Alopecia Areata","completionDate":"2010-11"},{"nctId":"NCT00367497","phase":"Phase 2","title":"Phase 2 Study of Rituximab and ESHAP (Etoposide, Methylprednisolone, Cytarabine, and Cisplatin) in Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Keio University","isPivotal":false,"enrollment":5,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2007-11"},{"nctId":"NCT04791345","phase":"Phase 1","title":"Study of the Excretion of Orally Administered Corticosteroids for the Improval of the Detection of Said Substances in Anti-doping Controls","status":"UNKNOWN","sponsor":"Parc de Salut Mar","isPivotal":false,"enrollment":50,"indication":"Healthy Volunteers","completionDate":"2022-02-26"},{"nctId":"NCT04501367","phase":"Phase 4","title":"Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) When Placed Within the Lower Eye Lid Canaliculus or Both the Upper and Lower Canaliculi for the Treatmen","status":"UNKNOWN","sponsor":"Kovach Eye Institute","isPivotal":false,"enrollment":60,"indication":"Vitrectomy, Macular Pucker","completionDate":"2024-12-31"},{"nctId":"NCT00004357","phase":"Phase 2","title":"Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis","status":"COMPLETED","sponsor":"Northwestern University","isPivotal":false,"enrollment":6,"indication":"Vasculitis, Hypersensitivity, Connective Tissue Diseases","completionDate":"2008-02"},{"nctId":"NCT03721965","phase":"Phase 1","title":"An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Pe","status":"TERMINATED","sponsor":"Incyte Corporation","isPivotal":false,"enrollment":2,"indication":"Acute Graft-versus-host Disease","completionDate":"2020-02-17"},{"nctId":"NCT00404469","phase":"NA","title":"Effects of Peritendinous Corticosteroid Injections, Eccentric Training and Heavy Slow Resistance Training in Patellar Tendinopathy","status":"COMPLETED","sponsor":"Bispebjerg Hospital","isPivotal":false,"enrollment":39,"indication":"Patellar Tendinopathy / Jumpers Knee","completionDate":"2007-11"},{"nctId":"NCT00426101","phase":"Phase 3","title":"HLH-2004 Treatment Protocol","status":"COMPLETED","sponsor":"Karolinska University Hospital","isPivotal":true,"enrollment":368,"indication":"Hemophagocytic Lymphohistiocytosis","completionDate":"2017-12"},{"nctId":"NCT00048165","phase":"Phase 4","title":"A Double-Blind, Placebo -Controlled, Randomized Study to Assess the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transp","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":false,"enrollment":434,"indication":"Heart Transplantation","completionDate":"2002-08"}],"whoEssential":true,"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Ophthalmic","frequency":"Once daily or divided doses","formulation":"Tablet, Oral solution, Eye drops, Injectable"},"crossReferences":{"unii":"8B2807733D","rxcui":"8638","splId":"bff1726c-7781-49de-8a61-bc37a755c92b","chemblId":"CHEMBL1201014","pubchemSID":"9573"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":34794,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"1955-01-01","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1995-12-29T00:00:00.000Z","mah":"BAUSCH AND LOMB","brand_name_local":null,"application_number":"ANDA074449"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2005-06-09T00:00:00.000Z","mah":"CHARTWELL RX","brand_name_local":null,"application_number":"ANDA075988"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-10-25T00:00:00.000Z","mah":"AMNEAL","brand_name_local":null,"application_number":"ANDA216715"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-06-05T00:00:00.000Z","mah":"PHARM ASSOC","brand_name_local":null,"application_number":"ANDA078988"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-06-05T00:00:00.000Z","mah":"LANNETT CO INC","brand_name_local":null,"application_number":"ANDA040775"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"46.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"46.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"46.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"46.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"46.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":6,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:42:44.927314+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}